Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Mablife
InventorsPhilippe Le Bouteiller, Armand Bensussan
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.
Claims13
A method for treating neovascular eye diseases associated with neoangiogenesis, comprising administering an anti-CD160 antibody and an anti-VEGF antibody to a subject in need thereof, wherein said anti-CD160 antibody is the CL1-R2 monoclonal antibody or an antigen-binding fragment thereof.
Dependencies are inferred from the claim text.